Anticoagulation plus immunosuppression for Behcet's vein clots
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This trial compares standard immunosuppressive therapy alone versus adding a blood thinner (rivaroxaban) for treating newly diagnosed blood clots in the legs of people with Behcet's disease. It aims to see if adding the anticoagulant improves clot resolution without increasing bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 50 years old
- Diagnosed with Behcet's disease
- Newly diagnosed blood clot in a leg vein within the last 14 days that has not been treated before
- No previous treatment for blood clots related to Behcet's disease (no prior immunosuppressants for blood vessel involvement)
- No aneurysm, active bleeding, severe kidney or liver disease, or history of cancer in the last 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a blood thinner (anticoagulant) to steroid therapy is more effective than steroids alone for treating deep vein thrombosis (a blood clot in a large vein) in people with Behçet's syndrome. It aims to find the best way to prevent future clots and reduce side effects.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This study looks at how Behçet's disease affects blood clotting. If you have Behçet's disease and are between 18–70, you may help doctors understand why some people with Behçet's develop dangerous blood clots.
This study looks at how the thickness of the femoral vein wall and certain markers of inflammation relate to Behcet disease. It may help doctors better understand and monitor the condition.
This trial tests an experimental pill, HSK44459, for people with Behçet's disease who have frequent mouth ulcers. It aims to see if the drug can safely reduce ulcer episodes and improve symptoms.
This trial tests if a full dose of rivaroxaban (a blood thinner) works better than a lower preventive dose for treating a superficial vein clot in the leg. It aims to find the safest and most effective way to stop the clot from getting worse or causing a more serious clot.
Hear when a new Behcet Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.